Prothrombin complex concentrates: Difference between revisions
Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Based on pretreatment INR, units based on factor 9 content | *Based on pretreatment INR, units based on factor 9 content | ||
** | **INR 2-4: 25units/kg, not to exceed 2500 units | ||
** | **INR 4-6: 35units/kg, not to exceed 3500 units | ||
**INR>6: 50units/kg, not to exceed 5000 units | **INR >6: 50units/kg, not to exceed 5000 units | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Safety and efficacy not established | Safety and efficacy not established |
Revision as of 17:57, 28 May 2015
General
- Type: Hemostatics, blood components
- Dosage Forms:lypophilized concentrate for reconstitution 500u/vial and 1000u/vial
- Common Trade Names: Kcentra
Adult Dosing
- Based on pretreatment INR, units based on factor 9 content
- INR 2-4: 25units/kg, not to exceed 2500 units
- INR 4-6: 35units/kg, not to exceed 3500 units
- INR >6: 50units/kg, not to exceed 5000 units
Pediatric Dosing
Safety and efficacy not established
Special Populations
- Pregnancy Rating: C
- Lactation: Unknown, breast feeding not advised
- Renal Dosing
- Adult-N/A
- Pediatric-N/A
- Hepatic Dosing
- Adult-N/A
- Pediatric-N/A
Contraindications
- Allergy to class/drug
- DIC
- known HIT (Heparin induced thrombocytopenia)
Serious
- thromboembolism
- blood product (hepatitis, HIV)
Common
- thromboembolic events (8.7%)
- headache (7.8%)
- hypotension (4.9%)
- nausea/vomiting
- arthralgia
- ICH (2.9%)
- mental status change (2.9%)
- hypertension (2.9%)
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
See Also
Sources
Medscape